Targeting COPD: Advances on low-molecular-weight inhibitors of human neutrophil elastase

Medicinal Research Reviews

Volumn 33, Issue SUPPL. 1, 2013, Pages

  Lucas, Susana D ^a   Costa, Elsa ^a   Guedes, Rita C ^a   Moreira, Rui ^a  

^a UNIVERSITY OF LISBON   (Portugal)

Author keywords

Acylating inhibitor; Human neutrophil elastase; Mechanism based inhibitor; Natural products; Transition state analog

Indexed keywords

2 PYRIDINYL ISOTHIAZOL 3(2H) ONE 1,1 DIOXIDE INHIBITOR; 2 PYRIDONE DERIVATIVE; AE 3763; AZD 9668; BAICALEIN; BETA LACTAM DERIVATIVE; CEPHALOSPORIN; CHRYSIN; CINNAMIC ACID DERIVATIVE; COUMARIN DERIVATIVE; FK 706; FLAVONE DERIVATIVE; FLAVONOID; FLAVONOL DERIVATIVE; FRESELESTAT; ISOCOUMARIN DERIVATIVE; LEUKOCYTE ELASTASE INHIBITOR; MIDESTEINE; NATURAL PRODUCT; PEPTIDYL TRIFLUOROMETHYL KETONE DERIVATIVE; PHENOL DERIVATIVE; QUERCETIN DERIVATIVE; SACCHARIN; SERINE PROTEINASE INHIBITOR; SIVELESTAT; UNCLASSIFIED DRUG; ZD 0892;

ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CRYSTAL STRUCTURE; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG SOLUBILITY; DRUG STABILITY; DRUG STRUCTURE; HUMAN; HYDROLYSIS; INFLAMMATORY DISEASE; LIVER FUNCTION; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); SIDE EFFECT; SUICIDE SUBSTRATE; X RAY CRYSTALLOGRAPHY;

ENZYME INHIBITORS; GLYCINE; HUMANS; MOLECULAR WEIGHT; PROTEINASE INHIBITORY PROTEINS, SECRETORY; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SERINE PROTEINASE INHIBITORS; SULFONAMIDES;

EID: 84876844793     PISSN: 01986325     EISSN: 10981128     Source Type: Journal    
DOI: 10.1002/med.20247     Document Type: Article

References (119)

1. Schechter I, Berger A. On the size of the active site in proteases. I. Papain. Biochem Biophys Res Commun 1967;27:157-162.
2. Source: http://www.who.int/respiratory/copd/en/(access date: 11/04/2011).
3. Bousquet J, Khaltaev N, editors. Global surveillance, prevention and control of chronic respiratory diseases: A comprehensive approach. Geneva: WHO Press; 2007.
4. Djekic UV, Gaggar A, Weathington NM. Attacking the multi-tiered proteolytic pathology of COPD: New insights from basic and translational studies. Pharmacol Ther 2009;121:132-146.
5. Barnes PJ, Stockley RA. COPD: Current therapeutic interventions and future approaches. Eur Respir J 2005;25:1084-1106.
6. Greene CM, McElvaney NG. Proteases and antiproteases in chronic neutrophilic lung disease - relevance to drug discovery. Br J Pharmacol 2009;158:1048-1058.
7. Ohbayashi H. Neutrophil elastase inhibitors as treatment for COPD. Expert Opin Investig Drugs 2002;11:965-980.
8. Donnelly LE, Rogers DF. Therapy for chronic obstructive pulmonary disease in the 21st century. Drugs 2003;63:1973-1998.
9. Korkmaz B, Moreau T, Gauthier F. Neutrophil elastase, proteinase 3 and cathepsin G: Physicochemical properties, activity and physiopathological functions. Biochimie 2008;90:227-242.
10. Pham CTN. Neutrophil serine proteases fine-tune the inflammatory response. Int J Biochem Cell B 2008;40:1317-1333.
11. Ohmoto K, Yamamoto T, Okuma M, Horiuchi T, Imanishi H, Odagaki Y, Kawabata K, Sekioka T, Hirota Y, Matsuoka S, Nakai H, Toda M, Cheronis JC, Spruce LW, Gyorkos A, Wieczorek M. Development of orally active nonpeptidic inhibitors of human neutrophil elastase. J Med Chem 2001;44:1268-1285.
12. Heutinck KM, ten Berge IJM, Hack CE, Hamann J, Rowshani AT. Serine proteases of the human immune system in health and disease. Mol Immunol 2010;47:1943-1955.
13. Voynow JA, Fischer BM, Zheng S. Proteases and cystic fibrosis. Int J Biochem Cell B 2008;40:1238-1245.
14. Wang Z, Chen F, Zhai R, Zhang L, Su L, Thompson T, Christiani DC. Plasma neutrophil elastase and elafin imbalance is associated with acute respiratory distress syndrome (ARDS) development. PLoS ONE 2009;4:1-10.
15. Kawabata K, Hagio T, Matsuoka S. The role of neutrophil elastase in acute lung injury. Eur J Pharmacol 2002;451:1-10.
16. Guay C, Laviolette M, Tremblay GM. Targeting serine proteases in asthma. Curr Top Med Chem 2006;6:393-402.
17. Meyer-Hoffert U, Wingertszahn J, Wiedow O. Human leukocyte elastase induces keratinocyte proliferation by epidermal growth factor receptor activation. J Investig Dermatol 2004;123:338-345.
18. Cawston TE, Young DA. Proteinases involved in matrix turnover during cartilage and bone breakdown. Cell Tissue Res 2010;339:221-235.
19. Sato T, Takahashi S, Mizumoto T, Harao M, Akizuki M, Takasugi M, Fukutomi T, Yamashita J-I. Neutrophil elastase and cancer. J Surg Oncol 2006;15:217-222.
20. Iwata K, Doi A, Ohji G, Oka H, Oba Y, Takimoto K, Igarashi W, Gremillion DH, Shimada T. Effect of neutrophil elastase inhibitor (sivelestat sodium) in the treatment of acute lung injury (ALI) and acute respiratory distress syndrome (ARDS): A systematic review and meta-analysis. Intern Med 2010;49:2423-2432.
21. Maryanoff BE, Costanzo MJ. Inhibitors of proteases and amide hydrolases that employ an alpha-ketoheterocycle as a key enabling functionality. Bioorg Med Chem 2008;16:1562-1595.
22. Ohbayashi H. Current synthetic inhibitors of human neutrophil elastase in 2005. Expert Opin Ther Pat 2005;15:759-771.
23. Bernstein PR, Edwards PD, Williams JC. 2 Inhibitors of human leukocyte elastase. In: Ellis GP, Luscombe DK, editors. Progress in medicinal chemistry, vol. 31. Amsterdam: Elsevier; 1994. pp 59-120.
24. Powers JC, Asgian JL, Ekici OD, James KE. Irreversible inhibitors of serine, cysteine, and threonine proteases. Chem Rev 2002;102:4639-4750.
25. Imaki K, Okada T, Nakayama Y, Nagao Y, Kobayashi K, Sakai Y, Mohri T, Amino T, Nakai H, Kawamura M. Non-peptidic inhibitors of human neutrophil elastase: The design and synthesis of sulfonanilide-containing inhibitors. Bioorg Med Chem 1996;4:2115-2134.
26. Nakayama Y, Odagaki Y, Fujita S, Matsuoka S, Hamanaka N, Nakai H, Toda M. Clarification of mechanism of human sputum elastase inhibition by a new inhibitor, ONO-5046, using electrospray ionization mass spectrometry. Bioorg Med Chem Lett 2002;12:2349-2353.
27. Rizzi M, Casale E, Ascenzi P, Fasano M, Aime S, Larosa C, Luisetti M, Bolognesi M. Crystal-structure and NMR investigation of the serine proteinase-inhibitor Mr889, a cyclic thiolic compound. J Chem Soc [Perkin 2] 1993:2253-2256.
28. Luisetti M, Sturani C, Sella D, Madonini E, Galavotti V, Bruno G, Peona V, Kucich U, Dagnino G, Rosenbloom J, Starcher B. MR889, a neutrophil elastase inhibitor, in patients with chronic obstructive pulmonary disease: A double-blind, randomized, placebo-controlled clinical trial. Eur Respir J 1996;9:1482-1486.
29. Abbenante G, Fairlie DP. Protease inhibitors in the clinic. Med Chem 2005;1:71-104.
30. Schepetkin IA, Khlebnikov AI, Quinn MT. N-benzoylpyrazoles are novel small-molecule inhibitors of human neutrophil elastase. J Med Chem 2007;50:4928-4938.
31. Khlebnikov AI, Schepetkin IA, Quinn MT. Structure-activity relationship analysis of N-benzoylpyrazoles for elastase inhibitory activity: A simplified approach using atom pair descriptors. Bioorg Med Chem 2008;16:2791-2802.
32. Teshima T, Griffin JC, Powers JC. A new class of heterocyclic serine protease inhibitors-Inhibition of human-leukocyte elastase, porcine pancreatic elastase, cathepsin-g, and bovine chymotrypsin-a-alpha with substituted benzoxazinones, quinazolines, and anthranilates. J Biol Chem 1982;257:5085-5091.
33. Radhakrishnan R, Presta LG, Meyer EF, Wildonger R. Crystal-structures of the complex of porcine pancreatic elastase with 2 valine-derived benzoxazinone inhibitors. J Mol Biol 1987;198:417-424.
34. Krantz A, Spencer RW, Tam TF, Liak TJ, Copp LJ, Thomas EM, Rafferty SP. Design and synthesis of 4h-3, 1-benzoxazin-4-ones as potent alternate substrate-inhibitors of human-leukocyte elastase. J Med Chem 1990;33:464-479.
35. Colson E, Wallach J, Hauteville M. Synthesis and anti-elastase properties of 6-amino-2-phenyl-4H-3, 1-benzoxazin-4-one aminoacyl and dipeptidyl derivatives. Biochimie 2005;87:223-230.
36. Shreder KR, Cajica J, Du LL, Fraser A, Hu Y, Kohno Y, Lin ECK, Liu SJ, Okerberg E, Pham L, Wu JY, Kozarich JW. Synthesis and optimization of 2-pyridin-3-yl-benzo[d][1, 3]oxazin-4-one based inhibitors of human neutrophil elastase. Bioorg Med Chem Lett 2009;19:4743-4746.
37. Shreder K, Hu Y, Fraser A, Kohno Y, Kojima A, Ishiyama J, Akihiko K, Junichi I, Yasu K, Ishiyama Y; Activx Biosciences Inc; Kyorin Discovery Res Lab; Shreder K; Hu Y; Fraser A; Kohno Y; Kojima A; Ishiyama J; Kyorin Pharm Co Ltd; Kyorin Seiyaku Kk, assignee. New benzoxazinone compounds are serine hydrolase inhibitors useful for treating e.g. pulmonary emphysema, acute respiratory distress syndrome, cystic pulmonary fibrosis, chronic rheumatoid arthritis and osteoarthritis. Patent WO2008036379-A2; WO2008036379-A3; US2008161290-A1; EP2066662-A2; NO200901353-A; KR2009068263-A; AU2007297597-A1; CN101535304-A; MX2009002960-A1; CA2664152-A1; JP2010504334-W. 2008.
38. Gütschow M, Neumann U. Novel thieno[2, 3-d][1, 3]oxazin-4-ones as inhibitors of human leukocyte elastase. J Med Chem 1998;41:1729-1740.
39. Gütschow M, Kuerschner L, Neumann U, Pietsch M, Loser R, Koglin N, Eger K. 2-(diethylamino)thieno 1, 3 oxazin-4-ones as stable inhibitors of human leukocyte elastase. J Med Chem 1999;42:5437-5447.
40. Santagati NA, Salerno L, Di Giacomo C, Vanella L, Ronsisvalle S. Inhibition of human leucocyte elastase by novel thieno-1, 3-oxazin-4-ones and thieno-1, 3-thioxazin-4-ones. Lett Drug Des Discov 2007;4:386-393.
41. Hacker HG, Grundmann F, Lohr F, Ottersbach PA, Zhou J, Schnakenburg G, Gütschow M. 2-Amino- and 2-alkylthio-4H-3, 1-benzothiazin-4-ones: Synthesis, interconversion and enzyme inhibitory activities. Molecules 2009;14:378-402.
42. Aranda MT, Perez-Faginas P, Gonzalez-Muniz R. An update on the synthesis of beta-lactams. Curr Org Synth 2009;6:325-341.
43. Xing BG, Rao JH, Liu RR. Novel beta-lactam antibiotics derivatives: Their new applications as gene reporters, antitumor prodrugs and enzyme inhibitors. Mini-Rev Med Chem 2008;8:455-471.
44. Doherty JB, Ashe BM, Argenbright LW, Barker PL, Bonney RJ, Chandler GO, Dahlgren ME, Dorn CP, Finke PE, Firestone RA, Fletcher D, Hagmann WK, Mumford R, Ogrady L, Maycock AL, Pisano JM, Shah SK, Thompson KR, Zimmerman M. Cephalosporin antibiotics can be modified to inhibit human-leukocyte elastase. Nature 1986;322:192-194.
45. Finke PE, Shah SK, Ashe BM, Ball RG, Blacklock TJ, Bonney RJ, Brause KA, Chandler GO, Cotton M, Davies P, Dellea PS, Dorn CP, Fletcher DS, Ogrady LA, Hagmann WK, Hand KM, Knight WB, Maycock AL, Mumford RA, Osinga DG, Sohar P, Thompson KR, Weston H, Doherty JB. Inhibition of human-leukocyte elastase.4. selection of a substituted cephalosporin (L-658, 758) as a topical aerosol. J Med Chem 1992;35:3731-3744.
46. Knight WB, Maycock AL, Green BG, Ashe BM, Gale P, Weston H, Finke PE, Hagmann WK, Shah SK, Doherty JB. Mechanism of inhibition of human-leukocyte elastase by 2 cephalosporin derivatives. Biochemistry 1992;31:4980-4986.
47. Cvetovich RJ, Chartrain M, Hartner FW, Roberge C, Amato JS, Grabowski EJJ. An asymmetric synthesis of L-694, 458, a human leukocyte elastase inhibitor, via novel enzyme resolution of beta-lactam esters. J Org Chem 1996;61:6575-6580.
48. Clemente A, Domingos A, Grancho AP, Iley J, Moreira R, Neres J, Palma N, Santana AB, Valente E. Design, synthesis and stability of N-acyloxymethyl- and N-aminocarbonyloxymethyl-2-azetidinones as human leukocyte elastase inhibitors. Bioorg Med Chem Lett 2001;11:1065-1068.
49. Moreira R, Santana AB, Iley J, Neres J, Douglas KT, Horton PN, Hursthouse MB. Design, synthesis, and enzymatic evaluation of N-1-acyloxyalkyl- and N-1-oxazolidin-2, 4-dion-5-yl-substituted beta-lactams as novel inhibitors of human leukocyte elastase. J Med Chem 2005;48:4861-4870.
50. Mulchande J, Martins L, Moreira R, Archer M, Oliveira TF, Iley J. The efficiency of C-4 substituents in activating the beta-lactam scaffold towards serine proteases and hydroxide ion. Org Biomol Chem 2007;5:2617-2626.
51. Oliveira TF, Mulchande J, Moreira R, Iley J, Archer M. Crystallization and preliminary diffraction studies of porcine pancreatic elastase in complex with a novel inhibitor. Protein Pept Lett 2007;14:93-95.
52. Beardsell M, Hinchliffe PS, Wood JM, Wilmouth RC, Schofield CJ, Page MI. beta-Sultams-A novel class of serine protease inhibitors. Chem Commun 2001:497-498.
53. Tsang WY, Ahmed N, Hemming K, Page MI. Reactivity and selectivity in the inhibition of elastase by 3-oxo-beta-sultams and in their hydrolysis. Org Biomol Chem 2007;5:3993-4000.
54. Mulchande J, Guedes RC, Tsang WY, Page MI, Moreira R, Iley J. Azetidine-2, 4-diones (4-oxo-beta-lactams) as scaffolds for designing elastase inhibitors. J Med Chem 2008;51:1783-1790.
55. Mulchande J, Oliveira R, Carrasco M, Gouveia L, Guedes RC, Iley J, Moreira R. 4-Oxo-beta-lactams (Azetidine-2, 4-diones) are potent and selective inhibitors of human leukocyte elastase. J Med Chem 2010;53:241-253.
56. Elriati A, Achilles K, Loose J, Otto HH. beta-Lactam derivatives as enzyme inhibitors: Peptidic derivatives of (RS)-2-Oxo-4-phenylazetidine-1-alkanoic acids. Monatsh Chem 2007;138:627-634.
57. Elriati A, Loose J, Mayrhofer R, Bergmann HJ, Otto HH. beta-Lactam derivatives as enzyme inhibitors: Halogenated beta-lactams and related compounds. Monatsh Chem 2008;139:835-846.
58. Sartor L, Pezzato E, Dell'Aica I, Caniato R, Biggin S, Garbisa S. Inhibition of matrix-proteases by polyphenols: Chemical insights for anti-inflammatory and anti-invasion drug design. Biochem Pharmacol 2002;64:229-237.
59. Dell'Aica I, Sartor L, Galletti P, Giacomini D, Quintavalla A, Calabrese F, Giacometti C, Brunetta E, Piazza F, Agostini C, Garbisa S. Inhibition of leukocyte elastase, polymorphonuclear chemoinvasion, and inflammation-triggered pulmonary fibrosis by a 4-alkyliden-beta-lactam with a galloyl moiety. J Pharmacol Exp Ther 2006;316:539-546.
60. Macdonald SJF, Belton DJ, Buckley DM, Spooner JE, Anson MS, Harrison LA, Mills K, Upton RJ, Dowle MD, Smith RA, Molloy CR, Risley C. Syntheses of trans-5-oxo-hexahydro-pyrrolo[3, 2-b]pyrroles and trans-5-oxo-hexahydro-furo[3, 2-b]pyrroles (pyrrolidine trans-lactams and trans-lactones): New pharmacophores for elastase inhibition. J Med Chem 1998;41:3919-3922.
61. Macdonald SJF, Dowle MD, Harrison LA, Shah P, Johnson MR, Inglis GGA, Clarke GDE, Smith RA, Humphreys D, Molloy CR, Amour A, Dixon M, Murkitt G, Godward RE, Padfield T, Skarzynski T, Singh OMP, Kumar KA, Fleetwood G, Hodgson ST, Hardy GW, Finch H. The discovery of a potent, intracellular, orally bioavailable, long duration inhibitor of human neutrophil elastase-GW311616A a development candidate. Bioorg Med Chem Lett 2001;11:895-898.
62. Macdonald SJF, Dowle MD, Harrison LA, Clarke GDE, Inglis GGA, Johnson MR, Shah P, Smith RA, Amour A, Fleetwood G, Humphreys DC, Molloy CR, Dixon M, Godward RE, Wonacott AJ, Singh OMP, Hodgson ST, Hardy GW. Discovery of further pyrrolidine trans-lactams as inhibitors of human neutrophil elastase (HNE) with potential as development candidates and the crystal structure of HNE complexed with an inhibitor (GW475151). J Med Chem 2002;45:3878-3890.
63. Edwards PD, Bernstein PR. Synthetic inhibitors of elastase. Med Res Rev 1994;14:127-194.
64. Imperiali B, Abeles RH. A versatile synthesis of peptidyl fluoromethyl ketones. Tetrahedron Lett 1986;27:135-138.
65. Bergeson SH, Edwards PD, Krell RD, Shaw A, Stein RL, Stein MM, Strimpler AM, Trainor DA, Wildonger RA, Wolanin DJ. Inhibition of human-leukocyte elastase by peptide trifluoromethyl ketones. Abstr Pap Am Chem S 1987;193:1-Medi.
66. Wright JL, Farmer SG, Churg A. Synthetic serine elastase inhibitor reduces cigarette smoke-induced emphysema in guinea pigs. Am J Resp Crit Care 2002;166:954-960.
67. Edwards PD, Andisik DW, Strimpler AM, Gomes B, Tuthill PA. Nonpeptidic inhibitors of human neutrophil elastase.7. Design, synthesis, and in vitro activity of a series of pyridopyrimidine trifluoromethyl ketones. J Med Chem 1996;39:1112-1124.
68. Shinguh Y, Imai K, Yamazaki A, Inamura N, Shima I, Wakabayashi A, Higashi Y, Ono T. Biochemical and pharmacological characterization of FK706, a novel elastase inhibitor. Eur J Pharmacol 1997;337:63-71.
69. Hansen P, Lawitz K, Lepistoe M, Loenn H, Ray A, Lepisto M, Lonn H. AstraZeneca AB (ASTR) Hansen P (Hans-Individual) Lawitz K (Lawi-Individual), assignee. New 2-pyridone compounds are human neutrophil elastase inhibitors useful to treat e.g. adult respiratory distress syndrome, cystic fibrosis, pulmonary emphysema, bronchitis, asthma, rhinitis, psoriasis, chronic wound and cancer. Patent WO2007129962-A1; EP2018375-A1; TW200808763-A; NO200804872-A; KR2009017573-A; US2009131486-A1; AU2007248950-A1; CN101490033-A; IN200809240-P1; MX2008013836-A1; JP2009536196-W; EP2018375-B1; DE602007005120-E. 2008.
70. Available from: http://www.clinicaltrials.gov/ct2/results?term=AZD9668 (access date: April 11, 2011).
71. Edwards PD, Meyer EF, Vijayalakshmi J, Tuthill PA, Andisik DA, Gomes B, Strimpler A. design, synthesis, and kinetic evaluation of a unique class of elastase inhibitors, the peptidyl alpha-ketobenzoxazoles, and the X-ray crystal-structure of the covalent complex between porcine pancreatic elastase and Ac-Ala-Pro-Val-2-Benzoxazole. J Am Chem Soc 1992;114:1854-1863.
72. Sato F, Inoue Y, Omodani T, Imano K, Okazaki H, Takemura T, Komiya M. Design and synthesis of peptide-based carboxylic acid-containing transition-state inhibitors of human neutrophil elastase. Bioorg Med Chem Lett 2002;12:551-555.
73. Inoue Y, Omodani T, Shiratake R, Okazaki H, Kuromiya A, Kubo T, Sato F. Development of a highly water-soluble peptide-based human neutrophil elastase inhibitor; AE-3763 for treatment of acute organ injury. Bioorg Med Chem 2009;17:7477-7486.
74. Ohmoto K, Yamamoto T, Horiuchi T, Imanishi H, Odagaki Y, Kawabata K, Sekioka T, Hirota Y, Matsuoka S, Nakai H, Toda M, Cheronis JC, Spruce LW, Gyorkos A, Wieczorek M. Design and synthesis of new orally active nonpeptidic inhibitors of human neutrophil elastase. J Med Chem 2000;43:4927-4929.
75. Zhong JY, Groutas WC. Recent developments in the design of mechanism-based and alternate substrate inhibitors of serine proteases. Curr Top Med Chem 2004;4:1203-1216.
76. Powers JC, Tuhy PM. Active-site specific inhibitors of elastase. J Am Chem Soc 1972;94:6544-6545.
77. Wei AZ, Mayr I, Bode W. The refined 2.3Å crystal-structure of human-leukocyte elastase in a complex with a valine chloromethyl ketone inhibitor. FEBS Lett 1988;234:367-373.
78. Pochet L, Frederick R, Masereel B. Coumarin and isocoumarin as serine protease inhibitors. Curr Pharm Des 2004;10:3781-3796.
79. Jakopin Z, Dolenc MS. Advances in the chemistry of saccharins: From synthetic novelties towards biologically active compounds. Curr Med Chem 2010;17:651-671.
80. Groutas WC, Brubaker MJ, Venkataraman R, Epp JB, Houserarchield N, Chong LS, Mcclenahan JJ. Potential mechanism-based inhibitors of proteolytic-enzymes. Bioorg Med Chem Lett 1992;2:175-180.
81. Groutas WC, Houserarchield N, Chong LS, Venkataraman R, Epp JB, Huang H, Mcclenahan JJ. Efficient inhibition of human-leukocyte elastase and cathepsin-G by saccharin derivatives. J Med Chem 1993;36:3178-3181.
82. Hlasta DJ, Subramanyam C, Bell MR, Carabateas PM, Court JJ, Desai RC, Drozd ML, Eickhoff WM, Ferguson EW, Gordon RJ, Johnson JA, Kumar V, Maycock AL, Mueller KR, Pagani ED, Robinson DT, Saindane MT, Silver PJ, Subramanian S, Dunlap RP, Franke CA, Mura AJ, Rowlands AG. Orally bioavailable benzisothiazolone inhibitors of human-leukocyte elastase. J Med Chem 1995;38:739-744.
83. Hlasta DJ, Ackerman JH, Mura AJ, Desai RC, Sterling Winthrop Inc; Sanofi; Sanofi Sa; Sanofi-Synthelabo, assignee. New saccharin derivatives are proteolytic enzyme inhibitors are useful in the treatment of degenerative diseases. Patent EP626378-A; EP626378-A1; AU9463280-A; NO9401937-A; US5378720-A; CZ9401268-A3; FI9402423-A; CA2122886-A; JP7070094-A; SK9400615-A3; US5466701-A; NZ260585-A; HU70760-T; AU685785-B; NO302474-B1; IL109780-A; SG55137-A1; RU2126798-C1; SK281020-B6; TW420679-A; CZ289573-B6; PH31435-A; EP626378-B1; KR334345-B; DE69432035-E. 1995.
84. Hlasta DJ, Desai RC, Court JJ; Sterling Winthrop Inc; Sanofi Winthrop Inc; Sanofi Pharm Inc, assignee. New 3-substituted saccharin derivatives useful as protease inhibitors used to treat degenerative diseases e.g. rheumatoid arthritis. Patent EP793494-A; WO9616649-A; US5494925-A; WO9616649-A1; AU9642483-A; NO9702451-A; EP793494-A1; FI9702309-A; HU77086-T; JP10510535-W; AU703719-B; NZ297342-A; MX9704030-A1; CN1173130-A. 1996.
85. Kumar V, Dunlap RP, Subramanyam C, Desai RC, Bell MR, Court JJ, Farrell RP, Saindane MT, Boaz NW, Hlasta DJ, Mura AJ; Sterling Winthrop Inc, assignee. Use of 2-saccharinyl-methyl-aryl carboxylate derivatives for treating degenerative disease, e.g. emphysema, rheumatoid arthritis, pancreatitis, cystic fibrosis, chronic bronchitis, etc. Patent US5597841-A. 1997.
86. Mura AJ, Desai RC, Court JJ, Saindane MT, Farrell RP, Boaz NW, Dunlap RP, Hlasta DJ, Kumar V, Bell MR, Subramanyam C; Sterling Winthrop Inc, assignee. New N-aroyloxymethyl-saccharin derivatives e.g. 4, 6-di:methoxy-2-saccharinyl:methyl 2, 6-di:chloro:benzoate useful as protease inhibitors for treating degenerative diseases e.g. emphysema, arthritis, cystic fibrosis. Patent US5512589-A. 1996.
87. Eilfeld A, Tanarro CMG, Frizler M, Sieler J, Schulze B, Gütschow M. Synthesis and elastase-inhibiting activity of 2-pyridinyl-isothiazol-3(2H)-one 1, 1-dioxides. Bioorg Med Chem 2008;16:8127-8135.
88. Zakharova VM, Brede O, Gütschow M, Kuznetsov MA, Zibinsky M, Sieler J, Schulze B. N, N′-Linked 1, 2-benzisothiazol-3(2H)-one 1, 1-dioxides: Synthesis, biological activity, and derived radicals. Tetrahedron 2010;66:379-384.
89. Groutas WC, Kuang RZ, Venkataraman R, Epp JB, Ruan SM, Prakash O. Structure-based design of a general class of mechanism-based inhibitors of the serine proteinases employing a novel amino acid-derived heterocyclic scaffold. Biochemistry-Us 1997;36:4739-4750.
90. Kuang RZ, Venkataraman R, Ruan SM, Groutas WC. Use of the 1, 2, 5-thiadiazolidin-3-one 1, 1 dioxide and isothiazolidin-3-one 1, 1 dioxide scaffolds in the design of potent inhibitors of serine proteinases. Bioorg Med Chem Lett 1998;8:539-544.
91. Groutas WC, Epp JB, Kuang RZ, Ruan SM, Chong LS, Venkataraman R, Tu J, He S, Yu HY, Fu QH, Li YH, Truong TM, Vu NT. 1, 2, 5-Thiadiazolidin-3-one 1, 1 dioxide: A powerful scaffold for probing the S′ subsites of (chymo)trypsin-like serine proteases. Arch Biochem Biophys 2001;385:162-169.
92. Groutas WC, He S, Kuang RZ, Ruan S, Tu J, Chan HK. Inhibition of serine proteases by functionalized sulfonamides coupled to the 1, 2, 5-thiadiazolidin-3-one 1, 1 dioxide scaffold. Bioorg Med Chem 2001;9:1543-1548.
93. He S, Kuang RZ, Venkataraman R, Tu J, Truong TM, Chan HK, Groutas WC. Potent inhibition of serine proteases by heterocyclic sulfide derivatives of 1, 2, 5-thiadiazolidin-3-one 1, 1 dioxide. Bioorg Med Chem 2000;8:1713-1717.
94. Kuang RZ, Epp JB, Ruan S, Chong LS, Venkataraman R, Tu J, He S, Truong TM, Groutas WC. Utilization of the 1, 2, 5-thiadiazolidin-3-one 1, 1 dioxide scaffold in the design of potent inhibitors of serine proteases: SAR studies using carboxylates. Bioorg Med Chem 2000;8:1005-1016.
95. Groutas WC, Kuang RZ, Ruan SM, Epp JB, Venkataraman R, Truong TM. Potent and specific inhibition of human leukocyte elastase, cathepsin g and proteinase 3 by sulfone derivatives employing the 1, 2, 5-thiadiazolidin-3-one 1, 1 dioxide scaffold. Bioorg Med Chem 1998;6:661-671.
96. Li Y, Dou DF, He GJ, Lushington GH, Groutas WC. Mechanism-based inhibitors of serine proteases with high selectivity through optimization of S′ subsite binding. Bioorg Med Chem 2009;17:3536-3542.
97. Huang WJ, Yamamoto Y, Li Y, Dou DF, Alliston KR, Hanzlik RP, Williams TD, Groutas WC. X-ray snapshot of the mechanism of inactivation of human neutrophil elastase by 1.2, 5-thiadiazolidin-3-one 1, 1-dioxide derivativest. J Med Chem 2008;51:2003-2008.
98. Dou D, He G, Alliston KR, Groutas WC. Dual function inhibitors of relevance to chronic obstructive pulmonary disease. Bioorg Med Chem Lett 2011; 21:3177-3180.
99. Wei LQ, Gan XD, Zhong HY, Alliston KR, Groutas WC. Noncovalent inhibitors of human leukocyte elastase based on the 4-imidazolidinone scaffold. Bioorg Med Chem 2003;11:5149-5153.
100. He GJ, Dou DF, Wei LQ, Alliston KR, Groutas WC. Inhibitors of human neutrophil elastase based on a highly functionalized N-amino-4-imidazolidinone scaffold. Eur J Med Chem 2010;45:4280-4287.
101. Siedle B, Hrenn A, Merfort I. Natural compounds as inhibitors of human neutrophil elastase. Planta Med 2007;73:401-420.
102. Melzig MF, Loser B, Ciesielski S. Inhibition of neutrophil elastase activity by phenolic compounds from plants. Pharmazie 2001;56:967-970.
103. Krenn L, Wollenweber E, Steyrleuthner K, Gorick C, Melzig MF. Contribution of methylated exudate flavonoids to the anti-inflammatory activity of Grindelia robusta. Fitoterapia 2009;80:267-269.
104. Sartor L, Pezzato E, Garbisa S. (-)Epigallocatechin-3-gallate inhibits leukocyte elastase: Potential of the phyto-factor in hindering inflammation, emphysema, and invasion. J Leukoc Biol 2002;71:73-79.
105. Loser B, Kruse SO, Melzig MF, Nahrstedt A. Inhibition of neutrophil elastase activity by cinnamic acid derivatives from Cimicifuga racemosa. Planta Med 2000;66:751-753.
106. Hamburger M, Riese U, Graf H, Melzig MF, Ciesielski S, Baumann D, Dittmann K, Wegner C. Constituents in evening primrose oil with radical scavenging, cyclooxygenase, and neutrophil elastase inhibitory activities. J Agric Food Chem 2002;50:5533-5538.
107. Siedle B, Murillo R, Hucke O, Labahn A, Merfort I. Structure activity relationship studies of cinnamic acid derivatives as inhibitors of human neutrophil elastase revealed by ligand docking calculations. Pharmazie 2003;58:337-339.
108. Steinbrecher T, Hrenn A, Dormann KL, Merfort I, Labahn A. Bornyl (3, 4, 5-trihydroxy)-cinnamate-An optimized human neutrophil elastase inhibitor designed by free energy calculations. Bioorg Med Chem 2008;16:2385-2390.
109. Matthew S, Ross C, Rocca JR, Paul VJ, Luesch H. Lyngbyastatin 4, a dolastatin 13 analogue with elastase and chymotrypsin inhibitory activity from the marine cyanobacterium Lyngbya confervoides. J Nat Prod 2007;70:124-127.
110. Taori K, Matthew S, Rocca JR, Paul VJ, Luesch H. Lyngbyastatins 5-7, potent elastase inhibitors from Floridian marine cyanobacteria, Lyngbya spp. J Nat Prod 2007;70:1593-1600.
111. Mehner C, Muller D, Kehraus S, Hautmann S, Gütschow M, Konig GM. New peptolides from the cyanobacterium Nostoc insulare as selective and potent inhibitors of human leukocyte elastase. Chembiochem 2008;9:2692-2703.
112. Gunasekera SP, Miller MW, Kwan JC, Luesch H, Paul VJ. Molassamide, a depsipeptide serine protease inhibitor from the marine cyanobacterium Dichothrix utahensis. J Nat Prod 2010;73:459-462.
113. Yunt Z, Reinhardt K, Li A, Engeser M, Dahse HM, Gütschow M, Bruhn T, Bringmann G, Piel J. Cleavage of four carbon-carbon bonds during biosynthesis of the griseorhodin a spiroketal pharmacophore. J Am Chem Soc 2009;131:2297-2305.
114. Sisay MT, Hautmann S, Mehner C, Konig GM, Bajorath J, Gütschow M. Inhibition of human leukocyte elastase by brunsvicamides a-C: Cyanobacterial cyclic peptides. Chem Med Chem 2009;4:1425-1429.
115. Brimert T, Lawitz K, Loenn H, Nikitidis A, Ray AK, Sandmark J, Lehmann HD, Lonn H, Ray A; AstraZeneca AB (ASTR), assignee. New 2-pyridone derivatives, useful for treating human diseases or conditions in which modulation of neutrophil elastase activity is beneficial e.g. adult respiratory distress syndrome, cystic fibrosis, pulmonary emphysema and bronchitis. Patent WO2006098684-A1; NO200705059-A; AU2006223675-A1; IN200706341-P1; EP1861371-A1; KR2007114154-A; CN101142188-A; JP2008533137-W; MX2007009372-A1; ZA200706761-A; US2009105239-A1; TW200700392-A; AU2006223675-B2; BR200608636-A2.
116. Anlauf S, Karthaus D, Klein M, Li VM, Lustig K, Meibom D, Nussbaum F, Schamberger J, Min-Jian LV; Bayer Schering Pharma Ag (Farb), assignee. New 4-(4-cyano-2-thioaryl)dihydropyrimidinone compounds are neutrophil elastase inhibitors useful to treat or prevent e.g. pulmonary arterial hypertension, chronic obstructive pulmonary disease, acute lung injury, or cystic fibrosis. Patent WO2009080199-A1; DE102008022521-A1; DE102008052013-A1.
117. Nussbaum F, Gielen-Haertwig H, Klein M, Li V, Meibom D, Sandner P, Lustig K, Schaefer S, Von Nussbaum F, Li VM; Bayer Healthcare Ag (Farb), assignee. Use of 1, 4-diaryl-dihydropyrimidin-2-one derivative for producing a medicament for the treatment and/or prophylaxis of e.g. pulmonary arterial hypertension, chronic-obstructive lung diseases and sleep apnea syndrome. Patent DE102006031314-A1; WO2008003412-A1; EP2037930-A1; CA2656307-A1; JP2009541384-W; US2010010024-A1.
118. Shreder K, Hu Y, Fraser A, Kohno Y, Kojima A, Ishiyama J, Akihiko K, Junichi I, Yasu K, Ishiyama Y; ActivX Biosciences Inc (ACTI-Non-standard) Kyorin Discovery Res Lab (KYOR-Non-standard) Kyorin Pharm Co Ltd (KYOR) Kyorin Seiyaku KK (KYOR), assignee. New benzoxazinone compounds are serine hydrolase inhibitors useful for treating e.g. pulmonary emphysema, acute respiratory distress syndrome, cystic pulmonary fibrosis, chronic rheumatoid arthritis and osteoarthritis. Patent WO2008036379-A2; WO2008036379-A3; US2008161290-A1; EP2066662-A2; NO200901353-A; KR2009068263-A; AU2007297597-A1; CN101535304-A; MX2009002960-A1; CA2664152-A1; JP2010504334-W.
119. Aprikyan AA, Dale DC, Finke PE, Mumford RA; Merck&Co Inc (Meri) Univ Washington (Uniw), assignee. Treating cyclic or severe congenital neutropenia, in a patient involves administering an elastase inhibitor. Patent WO2009035541-A1.